Abstract:Using diverse arylmethyl groups to replace the benzyl moiety of the lead Hsp90 inhibitor 1 (N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-N-benzyl-1,2,3,4-tetrahydro-3-iso quinolinecarboxamide), thirty four derivatives (10-43) were developed, and exhibited improved Hsp90 inhibitory and antiproliferative activities. SAR analysis indicated that the southeastern aryl substitutions influenced their antiproliferative activities obviously, with the para-pyridyl group (41) outperforming all other substitution patterns. In this regard, compound 41 was selected for further evaluation. CETSA melt and ITDRFCETSA (isothermal dose-response fingerprint) curves for Hsp90α further proved that 41 interacted with intracellular Hsp90α powerfully. Compared with the lead compound 1, docking and MD refinement of the Hsp90α-41 complex revealed a favorable H-bonding interaction between the side-chain of Tyr139 and the pyridine moiety of 41, which is the first time to be used for resorcinol-based Hsp90 inhibitors. With broad-spectral antitumor activity, compound 41 induced time- and dose-dependent growth inhibition and G0/G1 cell cycle arrest on human breast cancer MDA-MB-453 cell line. In addition, flow cytometry and Western blot analyses confirmed that 41 induced apoptosis of human breast cancer MDA-MB-453 cell line. Via degradation of IKKs and suppression of IKKs activity, compound 41 inhibited TNF-α-induced NF-κB activation. The overall properties warrant compound 41 a promising Hsp90 inhibitor and further biological characterizations. This study provides insights into the chemical evolution of Hsp90 inhibitors, and may facilitate the design of next generation Hsp90 inhibitors for the antitumor drug development.

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

Design, Synthesis and Biological Evaluation of Novel Tripeptidyl Epoxyketone Derivatives Constructed from Β-Amino Acid As Proteasome Inhibitors.

Design, Synthesis and Biological Evaluation of Triaryl Compounds As Novel 20S Proteasome Inhibitors.

Design and Synthesis of A Novel Class of Furan-Based Molecules As Potential 20s Proteasome Inhibitors

Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors.

Novel CADD-based Peptidyl Vinyl Ester Derivatives As Potential Proteasome Inhibitors

Exploration of Novel Macrocyclic Dipeptide N-benzyl Amides As Proteasome Inhibitors.

Design, Synthesis and Biological Evaluation of Dipeptides As Novel Non-Covalent 20S Proteasome Inhibitors

Preparation and Biological Evaluation of Soluble Tetrapeptide Epoxyketone Proteasome Inhibitors.

Design, Synthesis and Biological Evaluation of Tripeptide Boronic Acid Proteasome Inhibitors

Design and Synthesis of Tripeptidyl Furylketones As Selective Inhibitors Against the Β5 Subunit of Human 20S Proteasome

Discovery of Novel Covalent Proteasome Inhibitors Through a Combination of Pharmacophore Screening, Covalent Docking, and Molecular Dynamics Simulations.

Design, Synthesis and Cytotoxic Activity of a Novel Series of Steroidal Phenylpyrazoles.

Design, Synthesis and Biological Evaluation of Pyrrolidinone Analogs As Potential 20S Proteasome Inhibitors

Design, Synthesis and Biological Evaluation of Novel Antitumor Spirotetrahydrothiopyran-Oxindole Derivatives As Potent P53-Mdm2 Inhibitors

Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment

Exploration of novel four-membered-heterocycle constructed peptidyl proteasome inhibitors with improved metabolic stability for cancer treatment

Design, Combinatorial Synthesis and Biological Evaluations of Novel 3-Amino-1'-((1-aryl-1h-1,2,3-triazol-5-yl)methyl)-2'-oxospiro[benzo[a] Pyrano[2,3-C]phenazine-1,3'-indoline]-2-carbonitrile Antitumor Hybrid Molecules.

3D-QSAR-aided design, synthesis, in vitro and in vivo evaluation of dipeptidyl boronic acid proteasome inhibitors and mechanism studies

Design, Synthesis and Pharmacological Evaluation of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-N-arylmethyl-1,2,3,4-tetrahydro-3-isoquinolinecarboxamides As Potent Hsp90 Inhibitors.